ExploreWatchlistsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. EBITDA margin (%)

LIGAND PHARMACEUTICALS INC (LGND)

Market cap
$4.7B
P/E ratio
38.2x
SummaryFinancials
Period EndEBITDA margin (%) YoY (%)
Dec 31, 202527.9+269.02%
Dec 31, 20247.6-79.52%
Dec 31, 202336.9+32.72%
Dec 31, 202227.8-40.70%
Dec 31, 202146.9+69.64%
Dec 31, 202027.6-95.97%
Dec 31, 2019686.3+867.02%
Dec 31, 201871+25.50%
Dec 31, 201756.5+11.68%
Dec 31, 201650.6+21.55%
Dec 31, 201541.7+20.65%
Dec 31, 201434.5-3.96%
Dec 31, 201336+241.84%
Dec 31, 201210.5+51.00%
Dec 31, 20117

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat